Observational study collecting samples and data from people with Parkinson disease
Collects samples and health data from people with Parkinson disease and healthy controls over time.
Plain-language title generated from the registry record
Registry title: Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme
Key facts
- Where
- Luxembourg, LuxembourgSee the 2 sites
Where in Luxembourg
- Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic"Luxembourg, LuxembourgTaking people
- Clinical and Epidemiological Investigation Center (CIEC)Luxembourg, LuxembourgTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Luxembourg Institute of Health
- Trial code
- NCT05266872
- Record updated
- 14 September 2026
- Original description
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.Read full original descriptionShow less
Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.
Inclusion: Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism); Subjects of all genders with a full capacity of consent; Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement; Subjects of at least 18 years of age at the time of inclusion.
Exclusion: Active cancer; For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings; Underage subjects of less than 18 years of age; Refusal to sign the informed consent; Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion; Pregnant women; Refusal to comply with mandatory sample collection.